258 related articles for article (PubMed ID: 27803388)
1. Viral Vectors: The Road to Reducing Genotoxicity.
David RM; Doherty AT
Toxicol Sci; 2017 Feb; 155(2):315-325. PubMed ID: 27803388
[TBL] [Abstract][Full Text] [Related]
2. Foamy Virus Vector Carries a Strong Insulator in Its Long Terminal Repeat Which Reduces Its Genotoxic Potential.
Goodman MA; Arumugam P; Pillis DM; Loberg A; Nasimuzzaman M; Lynn D; van der Loo JCM; Dexheimer PJ; Keddache M; Bauer TR; Hickstein DD; Russell DW; Malik P
J Virol; 2018 Jan; 92(1):. PubMed ID: 29046446
[TBL] [Abstract][Full Text] [Related]
3. Monitoring for potential adverse effects of prenatal gene therapy: genotoxicity analysis in vitro and on small animal models ex vivo and in vivo.
Themis M
Methods Mol Biol; 2012; 891():341-70. PubMed ID: 22648780
[TBL] [Abstract][Full Text] [Related]
4. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity.
Modlich U; Bohne J; Schmidt M; von Kalle C; Knöss S; Schambach A; Baum C
Blood; 2006 Oct; 108(8):2545-53. PubMed ID: 16825499
[TBL] [Abstract][Full Text] [Related]
5. Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo.
Cesana D; Ranzani M; Volpin M; Bartholomae C; Duros C; Artus A; Merella S; Benedicenti F; Sergi Sergi L; Sanvito F; Brombin C; Nonis A; Serio CD; Doglioni C; von Kalle C; Schmidt M; Cohen-Haguenauer O; Naldini L; Montini E
Mol Ther; 2014 Apr; 22(4):774-85. PubMed ID: 24441399
[TBL] [Abstract][Full Text] [Related]
6. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy.
Montini E; Cesana D; Schmidt M; Sanvito F; Bartholomae CC; Ranzani M; Benedicenti F; Sergi LS; Ambrosi A; Ponzoni M; Doglioni C; Di Serio C; von Kalle C; Naldini L
J Clin Invest; 2009 Apr; 119(4):964-75. PubMed ID: 19307726
[TBL] [Abstract][Full Text] [Related]
7. Gene specificity of suppression of transgene-mediated insertional transcriptional activation by the chicken HS4 insulator.
Desprat R; Bouhassira EE
PLoS One; 2009 Jun; 4(6):e5956. PubMed ID: 19536296
[TBL] [Abstract][Full Text] [Related]
8. The retroviral vector family: something for everyone.
Elsner C; Bohne J
Virus Genes; 2017 Oct; 53(5):714-722. PubMed ID: 28762206
[TBL] [Abstract][Full Text] [Related]
9. Non-clinical safety assessment of novel drug modalities: Genome safety perspectives on viral-, nuclease- and nucleotide-based gene therapies.
Lemmens M; Dorsheimer L; Zeller A; Dietz-Baum Y
Mutat Res Genet Toxicol Environ Mutagen; 2024; 896():503767. PubMed ID: 38821669
[TBL] [Abstract][Full Text] [Related]
10. Preventing and exploiting the oncogenic potential of integrating gene vectors.
Modlich U; Baum C
J Clin Invest; 2009 Apr; 119(4):755-8. PubMed ID: 19348042
[TBL] [Abstract][Full Text] [Related]
11. Predicting genotoxicity of viral vectors for stem cell gene therapy using gene expression-based machine learning.
Schwarzer A; Talbot SR; Selich A; Morgan M; Schott JW; Dittrich-Breiholz O; Bastone AL; Weigel B; Ha TC; Dziadek V; Gijsbers R; Thrasher AJ; Staal FJT; Gaspar HB; Modlich U; Schambach A; Rothe M
Mol Ther; 2021 Dec; 29(12):3383-3397. PubMed ID: 34174440
[TBL] [Abstract][Full Text] [Related]
12. Biosafety challenges for use of lentiviral vectors in gene therapy.
Rothe M; Modlich U; Schambach A
Curr Gene Ther; 2013 Dec; 13(6):453-68. PubMed ID: 24195603
[TBL] [Abstract][Full Text] [Related]
13. Insertional gene activation by lentiviral and gammaretroviral vectors.
Bokhoven M; Stephen SL; Knight S; Gevers EF; Robinson IC; Takeuchi Y; Collins MK
J Virol; 2009 Jan; 83(1):283-94. PubMed ID: 18945765
[TBL] [Abstract][Full Text] [Related]
14. Assessing the potential for AAV vector genotoxicity in a murine model.
Li H; Malani N; Hamilton SR; Schlachterman A; Bussadori G; Edmonson SE; Shah R; Arruda VR; Mingozzi F; Wright JF; Bushman FD; High KA
Blood; 2011 Mar; 117(12):3311-9. PubMed ID: 21106988
[TBL] [Abstract][Full Text] [Related]
15. Challenges in CRISPR/CAS9 Delivery: Potential Roles of Nonviral Vectors.
Li L; He ZY; Wei XW; Gao GP; Wei YQ
Hum Gene Ther; 2015 Jul; 26(7):452-62. PubMed ID: 26176432
[TBL] [Abstract][Full Text] [Related]
16. Genotoxicity in gene therapy: an account of vector integration and designer nucleases.
Bohne J; Cathomen T
Curr Opin Mol Ther; 2008 Jun; 10(3):214-23. PubMed ID: 18535928
[TBL] [Abstract][Full Text] [Related]
17. Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity.
Wu C; Dunbar CE
Front Med; 2011 Dec; 5(4):356-71. PubMed ID: 22198747
[TBL] [Abstract][Full Text] [Related]
18. Genotoxicity assay for gene therapy vectors in tumor prone Cdkn2a⁻/⁻ mice.
Montini E; Cesana D
Methods Enzymol; 2012; 507():171-85. PubMed ID: 22365774
[TBL] [Abstract][Full Text] [Related]
19. Understanding lentiviral vector chromatin targeting: working to reduce insertional mutagenic potential for gene therapy.
Papayannakos C; Daniel R
Gene Ther; 2013 Jun; 20(6):581-8. PubMed ID: 23171920
[TBL] [Abstract][Full Text] [Related]
20. Evidence for the in vivo safety of insulated foamy viral vectors.
Browning DL; Everson EM; Leap DJ; Hocum JD; Wang H; Stamatoyannopoulos G; Trobridge GD
Gene Ther; 2017 Mar; 24(3):187-198. PubMed ID: 28024082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
